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Antibiotics may have bacteriostatic or bactericidal effects but may also cause immunomod-
ulation. Lipopeptides are known immunomodulators that interact with pattern recognition
receptors such as Toll-like receptors in antigen presenting cells. Daptomycin is a novel
lipopeptide antibiotic with a lipid moiety and unique structure that in the presence of diva-
lent ions may directly interact with lipid membrane phospholipids, the major component of
lipid membranes in immune cells. Daptomycin may also penetrate immune cells including
neutrophils and macrophages. However, the possible immunomodulatory effects of dap-
tomycin remain unknown. Understanding these effects is important to determine whether
this agent can provide protection against infectious challenge through multiple mecha-
nisms. Preliminary studies suggest that daptomycin may have minimal effects on cytokine
production and may have synergistic immunomodulatory effects in combination with other
immunomodulators.This review focuses on the hypothesis that daptomycin may also have
immunomodulatory effects but further studies are needed to investigate this hypothesis.
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INTRODUCTION
The increasing antimicrobial resistance represents a challenge in
treating infections (1, 2). The increased incidence of multidrug-
resistant gram-positive pathogens such as methicillin-resistant
Staphylococcus aureus (MRSA) (2) emphasizes the need for antimi-
crobials with different mechanisms of action (2). Daptomycin is
a lipopeptide antibiotic that is bactericidal against gram-positive
bacteria including MRSA (3). The Food and Drug Administra-
tion has approved daptomycin for the treatment of skin infections
caused by gram-positive pathogens and for the treatment of S.
aureus right-sided endocarditis and bacteremia (4). The exact
mechanism of action of this lipopeptide antibiotic remains to be
fully elucidated but its antimicrobial activity is entirely dependent
on calcium. Although some antibiotics may cause immunomod-
ulation (5–8) and lipopeptides are known immunomodulators
(9–11), the possible immunomodulatory effects of daptomycin
have been minimally investigated. In this review, the suggested
mechanism of action and the possible immunomodulatory role
of the lipopeptide antibiotic daptomycin are discussed.
DAPTOMYCIN, A PROTOTYPE OF THE ACIDIC LIPOPEPTIDE
FAMILY
Daptomycin is a cyclic anionic lipopeptide antibiotic that was
isolated from cultures of Streptomyces roseosporus (3, 12). This
lipopeptide consists of 13 amino acid residues, which include
3 exocyclic d-amino acid residues (d-asparagine, d-alanine, and
d-serine) and 3 non-proteinogenic amino acids including kynure-
nine (Kyn) that forms the macrolactone ring through an ester bond
with Thr (13). N -decanoyl fatty acid chain, consisting of 10–13
carbon atoms, attached to the N-terminal Trp-1 is also charac-
teristic (14, 15) (Figure 1). Thus, daptomycin has a lipophilic tail
and a water-soluble core consisting of 13 amino acids. Daptomycin
inherits a specific motif (DXDG), which is proposed to be involved
in Ca2+ binding (16). Several other calcium-dependent lipopep-
tide antibiotics are known, including calcium-dependent antibi-
otic (CDA) (17–19) and they also share a long chain fatty acid
attached to the cyclic core. The mechanistic and structural aspects
of non-ribosomal product assembly of this lipopeptide have been
previously reviewed in detail (20, 21).
MECHANISM OF ACTION OF DAPTOMYCIN
THE MECHANISM OF ACTION OF DAPTOMYCIN REMAINS UNCLEAR
BUT IS HIGHLY DEPENDENT ON DIVALENT IONS
Daptomycin acts bactericidal in a concentration-dependent man-
ner but the mechanism of action of daptomycin is still under
investigation (22). Daptomycin has a unique mode of antimicro-
bial action since free calcium ions at a concentration of 50 mg/l
are required for the drug to become active and to bind to the bac-
terial cytoplasmic membrane (23). Currently, mechanistic studies
largely focus on membrane insertion models and structures of
daptomycin in the presence and absence of Ca2+ and it has been
suggested that divalent cations promote formation of micelle by
interacting with the negatively charged components of bacterial
cell membranes such as phospholipids (14, 24) (Figure 1).
DIVALENT IONS INDUCE CONFORMATIONAL CHANGES IN
DAPTOMYCIN THAT FACILITATE INTERACTION OF DAPTOMYCIN WITH
THE CYTOPLASMIC MEMBRANE BILAYER
Jung et al. (25) proposed a two-step mechanism of action of
daptomycin that may explain how this lipopeptide interacts with
cytoplasmic membranes. Initially in the presence of Ca2+, dapto-
mycin binds to 1,2-dihexanoyl-sn-glycero-3-phosphocholine and
experiences a minor conformational rearrangement (14, 26). This
process increases amphipathicity of daptomycin, decreases its
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FIGURE 1 | Structure of daptomycin, a cyclic lipopeptide and interactions with the lipid bilayer.
charge, allows daptomycin to interact with neutral or acidic mem-
branes, and facilitates oligomerization (25) and micelle formation.
In a second step, daptomycin interacts with the acidic phospho-
lipids in the presence of Ca2+ and a major conformational change
allows daptomycin to insert into bilayer membranes with acidic
character (27, 28). In this model, the lipid tail promotes the for-
mation of micelles, which are vehicles to allow daptomycin to
insert into the bilayer (27), depolarize the membrane leading
to cell death (14, 22, 25) (Figure 1). Thus, similarly to cationic
peptides, the mechanism of action of daptomycin may involve
multiple targets (29).
DAPTOMYCIN DIRECTLY INTERACTS WITH PHOSPHOLIPIDS,
A COMPONENT OF LIPID MEMBRANES
Daptomycin can insert into artificial lipid vesicles and the mem-
brane of gram-positive bacteria (22, 25, 30). Daptomycin con-
tains two aromatic lipophilic residues (Trp-1 and Kyn-13) (30,
31) that upon their insertion in the phospholipid membrane
becomes less polar (22, 25, 30). Daptomycin directly interacts
with cytoplasmic membranes without requiring any receptors
(22, 25, 30) and can insert into membrane vesicles composed
of phosphatidylcholine (PC) and phosphatidylglycerol (PG) (25,
30). It has also been shown that daptomycin directly interacts
with pulmonary surfactant, which sequesters and inhibits the
antibiotic. Surfactant is composed mainly of dipalmitoylphos-
phatidylcholine and PG and only low levels of cholesterol and
sphingolipids contrary to most eukaryotic membranes (32). Sur-
factant is also ~10% negatively charged PG, a major component
of the gram-positive plasma membrane (33), which significantly
enhances insertion of surfactant into the membrane (25). The
major conformational change of daptomycin that leads to an
increased perturbation of the cytoplasmic membrane is dependent
on interaction with the bacterial acidic phospholipid,phosphatidyl
glycerol (34). Although binding of daptomycin to bilayers con-
taining acidic lipids primarily involves electrostatic interactions,
presumably through the Ca2+-induced electrostatic bridging of
the acidic amino acids in daptomycin with the acidic phospholipid
head groups, the binding of daptomycin to neutral bilayers may
occur through a combination of electrostatic and hydrophobic
interactions (25, 35).
LIPOPEPTIDES LIKE DAPTOMYCIN MAY DIRECTLY INTERACT
WITH THE LIPID MEMBRANES OF IMMUNE CELLS BUT THE
POSSIBLE IMMUNOMODULATORY EFFECTS OF
DAPTOMYCIN REMAIN UNKNOWN
IN THE PRESENCE OF CALCIUM, DAPTOMYCIN INTERACTS WITH
PHOSPHATIDYLCHOLINE, THE MAJOR COMPONENT OF LIPID
MEMBRANES IN EUKARYOTIC CELLS
Cell membrane lipids in eukaryotes consist mainly of glycerophos-
pholipids (GPLs), which are the major structural lipids in cellular
membranes (36, 37). Although the major conformational change
of daptomycin is dependent on interaction with the bacterial acidic
phospholipid, phosphatidyl glycerol, in the presence of calcium
daptomycin may directly interact with PC, which is the main
bilayer-forming lipid in eukaryotic cells including immune cells
(22, 25, 30). However, no studies have investigated the degree of
interaction of daptomycin with lipid membranes of immune cells
and further studies need to elucidate this possible interaction based
on the known immunomodulatory activity of other lipopeptides.
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LIPOPEPTIDES ARE KNOWN ADJUVANTS THAT MAY ENHANCE
IMMUNE RESPONSES
Adjuvants are substances that enhance the immune response in a
variety of ways including activation of pattern recognition recep-
tors (PRRs) on antigen presenting cells (APCs), which may result
in the upregulation of proteins, such as co-stimulatory molecules
and MHC class I and II (38–42). Most adjuvants are not phys-
ically associated with antigens and APCs could be activated by
the adjuvant without taking up the antigen. Lipid-based adjuvants
composed of lipopeptides, phosphatidylethanolamine (PE), PC,
liposomes, lipid A (41, 42), muramyl dipeptide derivatives (38–
40, 42) have previously been shown to exert immunopotentiating
effects and increase immune responses in vaccines often through
Fc receptor-mediated uptake and MHC class II presentation of
antigens (42–47).
MOST LIPOPEPTIDES INTERACT WITH TOLL-LIKE RECEPTORS
Lipopeptide adjuvants may form heterodimers with PRRs like
Toll-like receptors (TLRs) that are present on APCs including
macrophages and dendritic cells (9–11). Recognition by TLRs
leads to activation of innate immunity through upregulation of co-
stimulatory molecules and induction of inflammatory cytokines.
The discovery of TLRs and their role in lipopeptide recognition
contributed significantly to our understanding of how lipopep-
tides may interact with the immune system (48). Among several
hypotheses, including prevention of enzymatic peptide degrada-
tion, it has been suggested that the lipid moiety of lipopeptides
may be able to incorporate into cell membranes and deliver pep-
tide epitopes into the APCs (48, 49). Several lipopeptides impart
this self-adjuvanting activity by signaling via Toll-like receptor 2
(TLR2).
THE STRUCTURE OF LIPOPEPTIDES DETERMINES THEIR
IMMUNOPOTENTIATING EFFECTS
Lipopeptides consist of short structures of amino acids linked to
fatty acids via ester or amide bonds and the acyl chains are often
heterogeneous in terms of their length and degree of saturation.
Recent understanding of how the lipid component of lipopeptides
confers their activity as adjuvants could form the basis for vaccine
development against numerous diseases. Synthetic lipopeptides
have been used to determine the contribution of the lipid portion
of lipopeptide to TLR2 specific recognition (9, 50). Stereochemical
properties of the lipid moiety were found to influence aggrega-
tion behavior of the TLRs (51, 52). The activity of lipopeptides
is not only influenced by the number and type of fatty acids
present (9) but also on the position of the lipids (53). Lipopeptides
may form heterodimers with TLRs that are stabilized by hydrogen
bonding and hydrophobic interactions and may promote signal-
ing (54). However, although daptomycin is a lipopeptide that has
acyl groups and lipid moiety that could theoretically interact with
PRRs like TLRs, this remains to be shown experimentally and
the possible immunomodulatory effects of daptomycin have been
minimally studied.
THE INTERPLAY BETWEEN DAPTOMYCIN AND IMMUNITY
ANTIBIOTICS MAY HAVE IMMUNOMODULATORY EFFECTS
In addition to their antimicrobial activity, selected classes of antibi-
otics, like the macrolides, fluoroquinolones, oxazolidinones, and
fosfomycin are increasingly recognized to exert immunomod-
ulatory effects (5–8). Those antibiotics show large volumes of
distribution, are able to modulate cytokines, may accumulate
intracellularly in human blood and body cells to a varying extent,
potentially allowing them to interact with DNA and affecting
mRNA and protein synthesis (5–8). These immunomodulatory
effects of antimicrobials further emphasize the need to elucidate
the interplay between antibiotics and immunity, which may set the
basis for extended uses of certain antimicrobials especially in the
era of increased antimicrobial resistance. However, the possible
immunomodulatory effects of daptomycin remain unclear.
DAPTOMYCIN MAY PENETRATE INTO IMMUNE CELLS LIKE
NEUTROPHILS AND MACROPHAGES
Antibiotics may interact with bacteria intracellularly in phagocytes
(55, 56). Daptomycin may penetrate into human neutrophils and
thus may be effective in killing intracellular bacteria (57). In one
study, daptomycin had a 60% penetration to neutrophils (57). In
another study, daptomycin had potent intracellular antibacterial
effects against intracellular S. aureus in human monocyte-derived
macrophages (58). Two studies have demonstrated that intracellu-
lar daptomycin activity in macrophages depends on the concentra-
tion of the extracellular antibiotic and the duration of the exposure
to that concentration (55, 58). Thus, daptomycin may penetrate
into immune cells but the significance of this penetration with
regards to immunomodulation remains to be determined.
EFFECTS OF DAPTOMYCIN ON CYTOKINE PRODUCTION AND INNATE
IMMUNITY
Antibiotics may affect the overall balance of pro- and anti-
inflammatory cytokines. The ability of daptomycin to affect pro-
inflammatory cytokines was determined in one study by utilizing
an established whole blood in vitro model (59). Thallinger et al.
found that the addition of daptomycin at a therapeutically relevant
concentration of 40µg/ml in an experimental model of human
endotoxemia had no effect on cytokines such as interleukin-1β (IL-
1β), IL-6, and tumor necrosis factor alpha (TNF-α), neither on the
mRNA nor on the protein levels (59). In the experimental in vitro
study of Pichereau et al. on peripheral blood mononuclear cells,
many different antibiotics including daptomycin, tended to reduce
production of cytokines after toxin exposure (60). In the in vitro
study of English et al., exposure of S. aureus isolates to daptomycin
alone or in combination with vancomycin or oxacillin reduced
macrophage inflammatory responses such as tumor necrosis fac-
tor secretion and accumulation of inducible nitric oxide synthase
protein (compared with vancomycin or oxacillin alone) (61). The
lack of any significant immunomodulatory effect of daptomycin
observed in these preliminary studies may be explained by its
very low volume of distribution. Although daptomycin has been
shown to penetrate into immune cells (55–58), it remains to be
determined whether the penetration of daptomycin into human
cells is clinically significant because of the very hydrophilic, water-
soluble core of this antibiotic. However, the uptake of daptomycin
into mononuclear cells, which, beside the neutrophils, are mainly
responsible for cytokine production and release, occurs predomi-
nantly via phagocytosis and pinocytosis. The penetration of dapto-
mycin into the cell’s cytosol and nucleus is required for daptomycin
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to exert immunomodulatory effects on the human DNA (57, 58).
Thus, daptomycin may be less likely to affect levels of cytokines
probably due to high affinity of daptomycin to bacterial cyto-
plasmic membrane and its low potential to penetrate into human
cells (59). Further studies are needed to determine the effects of
daptomycin on cytokines. In one animal study in Balb/c mice,
daptomycin did not affect humoral and cell-mediated immune
responses such as polymorphonuclear phagocytic activity but the
concentrations of daptomycin used were not representative for the
concentrations used in humans after administration of standard
dosages (62). Thus, it is important that in all the in vitro and in vivo
studies testing immunomodulatory effects of antimicrobial agents,
the concentrations of daptomycin should be representative for the
concentrations used in humans after administration of standard
dosages. In addition, the use of whole blood instead of periph-
eral blood mononuclear cells, as frequently done in many in vitro
studies may reflect a more realistic clinical situation than the use
of isolated, selected immunocompetent blood cells.
DAPTOMYCIN MAY HAVE SYNERGISTIC IMMUNOMODULATORY
EFFECTS IN COMBINATION WITH OTHER IMMUNOMODULATORS LIKE
VITAMIN E
Vitamin E intake is associated with increased antimicrobial resis-
tance (63–65). Current data revealed immunomodulatory prop-
erties of vitamin E also in human peripheral mononuclear cells
altering cytokine production [interleukin (IL)-2, IL-8, and IL-17]
in part by stimulating production of cyclic adenosine monophos-
phate (cAMP) (66). In an animal model, administration of the
immune enhancer vitamin E before infecting 100 wounds by
MRSA improved later the efficacy of daptomycin (67). Addition-
ally, Pierpaoli et al. found that immune modulation was related to
the antimicrobial effect of vitamin E with or without daptomycin
(65). Gr-1+ cells and CD49b+ cells significantly increased in mice
treated with vitamin E while daptomycin alone did not affect
any of the leukocyte populations compared to control infected
animals (65). Vitamin E plus daptomycin significantly increased
CD49b+ cells compared with control infected animals or mice
treated with vitamin E alone (65). Thus in animals treated with
vitamin E with or without daptomycin, immunological changes
such as modulation of natural killer (NK) cell activity and changes
in leukocytes were associated with significant antibacterial activ-
ity (65). Further studies are needed to determine the possible
immunomodulatory effects of daptomycin in combination with
vitamins in humans (65).
DAPTOMYCIN AND NK CELL ACTIVITY
In one study, it was shown that administration of vitamin E plus
daptomycin was associated with modulation of NK cell activity
compared to controls (65). The groups given vitamin E plus dap-
tomycin had significant increase in NK activity and cytotoxicity
compared to vitamin E only or untreated animals suggesting an
association of the antimicrobial effects with the immune modu-
lation induced by the combination of daptomycin with vitamin E
(67). Daptomycin alone did not significantly enhance NK activ-
ity compared with untreated infected mice. NK cells may bridge
innate and adaptive immune responses and some of them respond
to a variety of lipid antigens (68). Further studies are needed to
FIGURE 2 | Possible immunomodulation related to daptomycin.
Immunological effects of lipopeptides have previously been described but
the interplay of daptomycin with immunity has been minimally studied.
understand the possible interaction between the lipid moiety of
lipopeptide antibiotics and NK cells (65).
CONCLUSION
Antibiotics may have bactericidal effects but may also cause
immunomodulation. Lipopeptides are known adjuvants and
immunomodulators that interact with PRRs such as TLRs in APCs.
Daptomycin is a novel lipopeptide antibiotic that is largely water-
soluble with a low volume of distribution but its lipid moiety and
unique structure in the presence of divalent ions contribute to
direct interaction with lipid membrane phospholipids. Although
daptomycin preferentially interacts with acidic phospholipids that
are present in the lipid membrane of gram-positive pathogens,
it may also directly interact with human surfactant and PC, the
major component of lipid membranes in immune cells. Dapto-
mycin may also penetrate immune cells including neutrophils and
macrophages. However, the possible immunomodulatory effects
of daptomycin remain unknown (Figure 2). Preliminary studies
suggest that daptomycin may have minimal effects on cytokine
production and may have synergistic immunomodulatory effects
(such as effects on NK cell activity) in combination with other
immunomodulators. Understanding whether daptomycin may be
an immunomodulatory agent is important to optimize the clinical
use of this agent, especially in the era of increased antimicrobial
resistance. Further studies are needed to investigate the interplay
between daptomycin and immunity.
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